Myriad Genetics arrives at its July 30 earnings release down 10% on the week and carrying the memory of a 17% one-day collapse after its last quarterly print in May.
The stock closed at $5.32 on Tuesday, extending a month-long slide that has now erased roughly 10% over 30 days. The setup is straightforward and uncomfortable: a company trading near multi-year lows, with analysts having cut targets twice in the past three months and no bull having lifted a finger since. The question heading into tomorrow's close is whether the May blowup — the worst single-session reaction in recent memory — repeats, or whether the ground has been cleared enough for a recovery.
Options traders are edging toward caution, though not dramatically so. The put/call ratio has crept above its recent average, running at 0.22 against a 20-day mean of 0.20, placing it roughly 1.6 standard deviations above that baseline. That's not a panic signal — the 52-week high PCR sits at 0.50, well above current levels — but the direction of travel matters. The ratio has risen steadily over the past two weeks as the stock has weakened, suggesting incremental demand for downside protection rather than outright fear. The borrow market, by contrast, is entirely relaxed. Availability is extraordinarily loose at over 6,800% — meaning there are roughly 68 shares available to lend for every one already borrowed. Cost to borrow dropped sharply on Tuesday to 0.54%, down from just over 1% on Sunday. Short interest itself, at 8.6% of the free float, ticked down nearly 9% on the week after what looks like a step-change reset on July 23. The short base is real but not growing, and the lending market offers no friction for anyone looking to add.
The Street has spent the past several months in a methodical retreat. Every recent analyst action has been a target cut with no rating change — TD Cowen moved to $6 from $7 in early May following the last earnings miss, Wells Fargo moved to $5.50 from $6 the same day. With the stock now at $5.32, Wells Fargo's target is barely above the current price. The consensus sits at Hold across all five covering analysts, and the mean target implies only modest upside. Valuation has compressed in sympathy: the price-to-earnings multiple has fallen roughly 16% over the past 30 days to around 49.7x, while price-to-book has slipped to 1.34. One genuinely positive signal comes from earnings estimate momentum — MYGN ranks in the 97th percentile on EPS surprise and the 90th on 30-day EPS momentum, suggesting analysts have been upgrading their forward numbers even as they've cut targets. The short score has also eased, dipping from 52 to 50 mid-week after the short interest reset, reflecting slightly lower bearish pressure in the composite signal.
Institutional ownership adds an interesting wrinkle. Glenview Capital — a healthcare-focused active manager — added 2.17 million shares in the March quarter to reach a 5.7% stake, making it the third-largest institutional holder. State Street added 866,000 shares through June. Those are not distressed-seller signals. Insider activity over the past 90 days has been net positive in shares at roughly 247,000 net shares, though the picture is mixed in composition: a director bought 7,500 shares at $3.69 in May, while the CEO sold 36,000 shares at $4.66 in March and the CCO sold nearly 56,000 shares in May. The net figure flatters the picture somewhat.
Earnings history makes the risk asymmetry plain. The May 5 print produced a 17% drop on the day and an 18% loss over five days. The June 4 event — which appears to have been a secondary report or rescheduled announcement — produced a 3.9% gain with a 5.2% five-day follow-through. Those are a wide range of outcomes. With the stock already down 10% heading into the release, the question tomorrow is less about the headline number and more about whether management can change the tone on hereditary testing volumes and the electronic medical record integration issues that drove the May selloff.
What to watch: the gap between MYGN's improving EPS estimate momentum and the Street's still-cautious ratings — if tomorrow's print closes that gap, the response in short covering and analyst target revision is the variable worth tracking.
See the live data behind this article on ORTEX.
Open MYGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
